Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy
暂无分享,去创建一个
[1] C. Foti,et al. The Intriguing Links between Psoriasis and Bullous Pemphigoid , 2022, Journal of clinical medicine.
[2] A. Offidani,et al. Bullous Pemphygoid and Novel Therapeutic Approaches , 2022, Biomedicines.
[3] W. Li,et al. Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid , 2022, The Journal of dermatology.
[4] T. Tsai,et al. Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review , 2022, American Journal of Clinical Dermatology.
[5] R. Bergman,et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV) , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.
[6] K. Schäkel,et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO) , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.
[7] Ying Xie,et al. Coexistence of Anti-p200 Pemphigoid and Psoriasis: A Systematic Review , 2022, Frontiers in Immunology.
[8] C. McCormack,et al. Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report , 2022, The Australasian journal of dermatology.
[9] M. Alaibac,et al. Bullous pemphigoid: An immune disorder related to aging (Review). , 2021, Experimental and therapeutic medicine.
[10] Lingyi Lu,et al. Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis , 2021, The Journal of dermatology.
[11] J. Sinagra,et al. Bullous Pemphigoid: Trigger and Predisposing Factors , 2020, Biomolecules.
[12] D. Zillikens,et al. Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[13] K. Kridin,et al. The Bidirectional Association Between Bullous Pemphigoid and Psoriasis: A Population-Based Cohort Study , 2020, Frontiers in Medicine.
[14] K. Kridin,et al. Increased Risk of Pemphigus among Patients with Psoriasis: A Large-scale Cohort Study , 2020, Acta dermato-venereologica.
[15] G. Ogg,et al. Role of regulatory T cells in psoriasis pathogenesis and treatment , 2020, The British journal of dermatology.
[16] M. Amagai,et al. Autoimmune bullous skin diseases, pemphigus and pemphigoid. , 2020, The Journal of allergy and clinical immunology.
[17] O. Abbas,et al. Update on the use of dapsone in dermatology , 2020, International journal of dermatology.
[18] Y. Tada,et al. Secukinumab decreased circulating anti‐BP180‐NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid , 2019, The Journal of dermatology.
[19] H. Busch,et al. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. , 2019, Journal of autoimmunity.
[20] J. Krueger,et al. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis , 2018, The Journal of Immunology.
[21] K. Phan,et al. Association between bullous pemphigoid and psoriasis: Systematic review and meta‐analysis of case‐control studies , 2018, The Australasian journal of dermatology.
[22] T. Dainichi,et al. Interaction of Psoriasis and Bullous Diseases , 2018, Front. Med..
[23] W. Boehncke,et al. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond , 2018, Front. Immunol..
[24] M. Schön,et al. The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis , 2018, Front. Immunol..
[25] L. Bonifaz,et al. SEB Stimulation Induces Functional Pathogenic Features in Th17 Cells from Psoriasis Patients. , 2018, The Journal of investigative dermatology.
[26] M. Furue,et al. Autoimmunity and autoimmune co‐morbidities in psoriasis , 2018, Immunology.
[27] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[28] T. Tsai,et al. Development of bullous pemphigoid during secukinumab treatment for psoriasis , 2017, The Journal of dermatology.
[29] F. Antonicelli,et al. A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[30] S. Langan,et al. Psoriasis and comorbid diseases: Epidemiology. , 2017, Journal of the American Academy of Dermatology.
[31] F. Antonicelli,et al. Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome , 2015, Scientific Reports.
[32] H. Koga,et al. Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases. , 2015, Journal of the American Academy of Dermatology.
[33] H. Koenen,et al. Cellular sources of IL‐17 in psoriasis: a paradigm shift? , 2014, Experimental dermatology.
[34] J. Blalock,et al. Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid , 2014, The Journal of investigative dermatology.
[35] O. FitzGerald,et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis , 2013, Arthritis Research & Therapy.
[36] U. Mrowietz,et al. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[37] O. Stasikowska-Kanicka,et al. IL-17 Expression in Dermatitis Herpetiformis and Bullous Pemphigoid , 2013, Mediators of inflammation.
[38] R. Schwartz,et al. Cardiovascular aspects of psoriasis: an updated review , 2013, International journal of dermatology.
[39] D. Tokunaga,et al. Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept , 2013, The Journal of dermatology.
[40] L. Herrinton,et al. The association of psoriasis with autoimmune diseases. , 2012, Journal of the American Academy of Dermatology.
[41] P. Mortensen. EPIDEMIOLOGY , 2012, Schizophrenia Research.
[42] T. Dainichi,et al. Lesional Th17 cells and regulatory T cells in bullous pemphigoid , 2011, Experimental dermatology.
[43] R. Rashmi,et al. The role of drugs in the induction and/or exacerbation of psoriasis , 2010, International journal of dermatology.
[44] J. Bystryn,et al. Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid. , 2010, Medical hypotheses.
[45] S. Vassileva. Drug-induced pemphigoid: bullous and cicatricial. , 1998, Clinics in dermatology.
[46] T. Hashimoto,et al. Psoriasis vulgaris coexistent with epidermolysis bullosa acquisita , 1997, The British journal of dermatology.
[47] H. Shimizu,et al. Coexistence of psoriasis and an unusual IgG‐mediated subepidermal bullous dermatosis: identification of a novel 200‐kDa lower lamina lucida target antigen , 1996, The British journal of dermatology.
[48] N. Tsankov,et al. Burn-induced bullous pemphigoid. , 1994, Journal of the American Academy of Dermatology.
[49] B. Stephens. The Beat Goes On , 1991, Science.
[50] A. Menter,et al. Erythrodermic psoriasis: Precipitating factors, course, and prognosis in 50 patients , 1989 .
[51] P. Aronson,et al. Bullous pemphigoid in psoriatic lesions. , 1989, Journal of the American Academy of Dermatology.
[52] N. Tsankov,et al. Psoriasis and drugs: influence of tetracyclines on the course of psoriasis. , 1988, Journal of the American Academy of Dermatology.
[53] N. Tsankov,et al. ONSET OF PSORIASIS COINCIDENT WITH TETRACYCLINE THERAPY , 1988, The Australasian journal of dermatology.
[54] C. Grattan. Evidence of an association between bullous pemphigoid and psoriasis , 1985, The British journal of dermatology.
[55] M. David,et al. Coexistence of psoriasis vulgaris and bullous diseases. , 1985, Journal of the American Academy of Dermatology.
[56] M. Lebwohl,et al. Biologics and Psoriasis: The Beat Goes On. , 2019, Dermatologic clinics.
[57] J. Wardle,et al. Sleep and nighttime energy consumption in early childhood: a population‐based cohort study , 2015, Pediatric obesity.
[58] D. C. Henckel,et al. Case report. , 1995, Journal.
[59] Robert C. Wolpert,et al. A Review of the , 1985 .